PCG Digital: Lexaria Is Expanding CBD Use Beyond Medical Applications into $2.65 Billion Marketplace New York, New York--(Newsfile Corp. - April 8, 2021) - PCG Digital -- The team at Lexaria Bioscience (NASDAQ: LEXX), a leader in cannabinoid research, has been thinking outside the box. Utilizing DehydraTECH TM, their proprietary drug delivery technology, they are showing that its benefits can enrich more than just CBD medical applications. Though they are currently executing groundbreaking work in anti-hypertension solutions, Lexaria received their first patent in 2016 for CBD-infused beverages and consumable liquids. That was years before big cannabis companies entered the space. DehydraTECH TM was developed to facilitate the delivery of fat-soluble molecules through the human gastrointestinal system. Extensive testing has shown that it reduces the time for CBD to enter the bloodstream, increases absorption rate, and improves taste and smell.